Morningstar

Curaleaf Holdings Inc CURA

Morningstar Rating
Unlock
Stock XTSE Rating as of
CAD 4.12 +0.02 (0.49%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Curaleaf Offers Unique Investment Exposure to Both International Medical and American Cannabis

Kristoffer Inton

Curaleaf cultivates and sells cannabis in the US with a presence in 17 states. Vertically integrated, Curaleaf produces through 19 cultivation sites and sells directly through 149 dispensaries and wholesale to other dispensaries. Compared with other multistate operators, Curaleaf has generally employed a more aggressive growth strategy, which hasn't always paid off, leading to exits and sales.

Read Full Report

Price vs Fair Value

View History
CURA is trading at a 788% premium.
Price
CAD 4.12
Fair Value
CAD 99.10
Uncertainty
Very High
1-Star Price
CAD 84.43
5-Star Price
CAD 4.45
Economic Moat
Tswww
Capital Allocation
Srdrrbzd

Bulls Say, Bears Say

Bulls

Unique among US multistate operators, Curaleaf's acquisitions into Europe and Canada allow it to serve the growing European market as legalization expands.

Bears

Sales growth for legal sellers like Curaleaf are challenged by the lack of taxes in the illicit market.

Show More

News

View All

Trading Information

Previous Close Price
CAD 4.10
Day Range
CAD 4.07–4.16
52-Week Range
CAD 3.65–8.73
Bid/Ask
CAD 4.07 / CAD 4.14
Market Cap
CAD 3.06 Bil
Volume/Avg
156,844 / 271,364

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
1.64
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
—

Company Profile

Curaleaf is headquartered in Wakefield, Massachusetts, and cultivates and sells medicinal and recreational cannabis in the US. The company has operations in 17 states. Its brands include Curaleaf, Select, and Grassroots. The company has made acquisitions that give it exposure to the growing European market, a unique feature among US multistate operators.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Small Growth
Total Number of Employees
5,650
Website
https://www.curaleaf.com

Competitors

Valuation

View More
Metric
CURA
GTII
CGC
Price/Earnings (Normalized)
 —33.07—
Price/Book Value
 2.251.390.95
Price/Sales
 1.642.251.74
Price/Cash Flow
 44.438.93—
Price/Earnings
CURA
GTII
CGC

Financial Strength

Metric
CURA
GTII
CGC
Quick Ratio
 0.400.671.48
Current Ratio
 1.091.092.15
Interest Coverage
 −0.228.03−5.32
Quick Ratio
CURA
GTII
CGC

Profitability

Metric
CURA
GTII
CGC
Return on Assets (Normalized)
 −2.85%4.40%−15.23%
Return on Equity (Normalized)
 −8.42%6.49%−37.47%
Return on Invested Capital (Normalized)
 −0.13%5.51%−11.79%
Return on Assets
CURA
GTII
CGC

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
YcppyyzzrLxwy$88.3 Bil
 Merck KGaA ADR
MKKGY
FttkmjzqqNtkclg$78.0 Bil
 Haleon PLC ADR
HLN
DtrhwpgrmDbztm$48.4 Bil
 Viatris Inc
VTRS
FgmczcbvYxgv$13.8 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
GdgdphnvRbfl$13.5 Bil
 Catalent Inc
CTLT
HwnxbwwkZppkfdf$10.9 Bil
 Prestige Consumer Healthcare Inc
PBH
MygpsbjsVgqzs$3.5 Bil
 Perrigo Co PLC
PRGO
QnyvwscgzSsnb$3.5 Bil
 Green Thumb Industries Inc
GTBIF
PsgnsxlfyWdrt$2.5 Bil
 Curaleaf Holdings Inc
CURLF
NxzvwcqHvbl$2.3 Bil

Sponsor Center